Stoke Therapeutics (STOK) Enterprise Value (2018 - 2026)

Stoke Therapeutics' Enterprise Value history runs 9 years deep, the most recent figure standing at -$343.5 million for Q1 2026.

• In Q1 2026, Enterprise Value rose 3.86% year-over-year to -$343.5 million; the TTM figure through Mar 2026 stood at -$343.5 million (up 3.86% YoY), while the FY2025 annual figure was -$284.7 million, down 31.25% from the prior year.
• Enterprise Value was -$343.5 million for Q1 2026 at Stoke Therapeutics, down from -$284.7 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$83.4 million in Q3 2025 to a low of -$357.3 million in Q1 2025.
• Historically, Enterprise Value has averaged -$227.1 million across 5 years, with a median of -$229.6 million in 2022.
• Biggest YoY gain for Enterprise Value was 47.53% in 2025; the steepest drop was 100.09% in 2025.
• A 5-year view of Enterprise Value shows it stood at -$229.6 million in 2022, then gained by 12.28% to -$201.4 million in 2023, then retreated by 7.7% to -$216.9 million in 2024, then sank by 31.25% to -$284.7 million in 2025, then slipped by 20.68% to -$343.5 million in 2026.
• The last three Enterprise Value figures came in at -$343.5 million (Q1 2026), -$284.7 million (Q4 2025), and -$83.4 million (Q3 2025), per Business Quant data.